KFKohei Fujita

Kohei Fujita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kohei Fujita has a total of 275 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World Outcomes and Early Progressive Disease Analysis of Nivolumab and Ipilimumab Combination Therapy in Metastatic NSCLC: LIGHT-NING Study 2.5-Year Update

    by Hisao Imai, Teppei Yamaguchi, Koichi Azuma, Takashi Kijima, Yukihiro Toi, Kazuma Kishi, Kohei Fujita, Haruhiro Saito, Yoshimasa Shiraishi, Junko Tanizaki, et al.

  • Open Access

    Serious abdominal complications during amivantamab-containing therapy in two patients with EGFR-mutated non-small cell lung cancer: case series

    by Naoki Fujimoto, Kohei Fujita, Hiroki Fukuda, Saiki Yoshimura, Shogo Toyama, Takanori Ito, Takuma Imakita, Issei Oi, Osamu Kanai, Kiminobu Tanizawa

  • Open Access

    Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre

    by Kohei Fujita, Takuma Imakita, Naoki Fujimoto, Saiki Yoshimura, Shogo Toyama, Takanori Ito, Issei Oi, Osamu Kanai, Yuki Yamamoto, Kiminobu Tanizawa

    1. Lung cancer, including tracheal and bronchial cancer, was the world’s most commonly diagnosed cancer and the leading cause of cancer death in 2022. There were 2.48 million new cases and 1.82 mil...

  • Open Access

    Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR ‐Mutated Advanced NSCLC : The Impact of Post‐Progression Management

    by Issei Oi, Kohei Fujita, Takuma Imakita, Mitsuhiro Tukino, Tetsuo Noguchi, Yuta Okada, Saiki Yoshimura, Naoki Fujimoto, Shogo Toyama, Atsuko Watanabe, et al.

    Background: Osimertinib is the standard first‐line treatment for epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung cancer (NSCLC). However, the impact of dose‐reduction on survival and the role of post‐progression management in real‐world settings remain unclear. Methods: We conducted a multi‐institutional retrospective cohort study on patients with EGFR‐mutated advanced NSCLC who received first‐line osimertinib between January 2018 and December 2023. Patients were classified into dose‐reduced and full‐dose groups. Primary endpoints were time to treatment failure (TTF) and overall survival (OS). The subsequent treatment after progression was also exploratively assessed to evaluate the impact of initial dose modification on the entire treatment sequence. Results: A total of 90 patients were analyzed, consisting of 61 patients in the full‐dose group and 29 in the dose‐reduction group. Median follow‐up was 21.5 months (IQR 9.1–37.2). The dose‐reduced group had significantly worse baseline performance status (PS) (PS 2–3: 37.9% vs. 14.8%, p = 0.014). Despite this, dose reduction showed no significant impact on TTF (adjusted HR 0.66, 95% CI 0.40–1.10, p = 0.11) or OS (HR 0.97, 95% CI 0.59–1.58, p = 0.89). Multivariate analysis revealed that transition to best supportive care (BSC) after progression, rather than initial dose reduction, was associated with OS (hazard ratio, 7.40; p < 0.0001). The proportions of patients receiving subsequent chemotherapy were comparable between the groups. Conclusions: Osimertinib dose reduction in the first‐line setting was not associated with inferior OS, suggesting that appropriate dose modification helps maintain PS. Transition to BSC after progression, rather than initial dose intensity, was associated with poor prognosis.

  • Open Access

    A single-centre analysis of the clinical characteristics of non-tuberculous mycobacterial lung disease caused by rare species

    by K. Fujita, O. Kanai, N. Fujimoto, S. Yoshimura, S. Toyama, T. Ito, T. Imakita, I. Oi, Y. Yamamoto, K. Tanizawa

    LETTER in IJTLD Open | Volume 3, Issue 6 A single-centre analysis of the clinical characteristics of non-tuberculous mycobacterial lung disease caused by rare species Fujita, K. Kanai, O. Fujimoto, N. Yoshimura, S. Toyama, S. Ito, T. Imakita, T. Oi, I. Yamamoto, Y. Tanizawa, K. IJTLD Open Vol 3 Issue 6 , Jun 2026, DOI: 10.5588/ijtldopen.26.0123 Focus Previous Next Article Figures & Tables Metrics Info Dear Editor, Non-tuberculous mycobacteria (NTM) comprise approximately 200 distinct species, of which around 30 have been documented to exhibit pathogenicity in humans.1 The epidemiological landscape of NTM demonstrates considerable geographical heterogeneity,2,3 but global surveillance data consistently indicate that the Mycobacterium avium complex (MAC) accounts for approximately 60% of all NTM isolates, followed by M. abscessus at 20%, M. kansasii at 10%, and other miscellaneous species collectively representing the remaining 10%.3,4 Rare NTM species, each with a detection rate below 1%, are encountered infrequently in routine clinical practice and present significant diagnostic and therapeutic challenges.4 Current clinical practice guidelines, including those established by the American Thoracic Society (ATS) and the European Respiratory Society (ERS), provide treatment recommendations exclusively for MAC, M. abscessus, and M. kansasii,2,5 but therapeutic guidance for other NTM species remains conspicuously absent from these evidence-based frameworks, reflecting the paucity of robust clinical trial data and limited understanding of the behaviour of these organisms.6 Consequently, the clinical management of NTM lung disease caused by rare species is largely left to the discretion of individual clinicians, both domestically and internationally.4,7 The rarity of these infections precludes large-scale randomised controlled trials, considerable heterogeneity in antimicrobial susceptibility patterns among rare species, and a lack of systematic documentation of treatment outcomes.6,8 This study aimed to provide valuable empirical evidence to inform clinical decision making in the absence of formal guidelines.2,6 This retrospective cohort study was conducted at the NHO Kyoto Medical Centre, Japan. For this investigation, rare NTM species were operationally defined as those with detection frequencies of approximately 1% or less. Patients were deemed eligible for inclusion if they fulfilled the diagnostic criteria of the 2007 ATS/IDSA statement and the 2020 ATS/ERS/ESCMID/IDSA clinical practice guidelines.2,5 We assessed the distribution of rare NTM species, the proportion of patients who met the diagnostic criteria caused by rare species, and the proportion of patients who underwent therapeutic intervention and clinical outcomes. The frequency and severity of treatment-related adverse events were categorised according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.9 This study was approved by the Institutional Review Board of the NHO Kyoto Medical Centre (approval number: 26-065). Seventeen rare NTM species were detected in 45 patients (see Table 1). The five most frequently detected NTM species were M. gordonae, M. lentiflavum, M. fortuitum, M. mageritense, and M. paragordonae. Of the 45 patients, 17 (37.8%) met the diagnostic criteria. Diagnoses were based on sputum culture (n = 11) or bronchoalveolar lavage (n = 6). The median age was 76.5 years (range, 56–89 years), and six patients (35.3%) were female. The radiological patterns were nodular bronchiectatic (n = 13), fibrocavitary (n = 2), or unclassifiable (n = 2). The most common co-morbidities were malignancy (29.4%) and COPD (23.5%). Clinical course of the treated and untreated patients is shown in Table 2. Treatment was initiated in 5 cases, whereas the remaining 12 cases were managed with observation alone. The reasons for observation were patient refusal (n = 7), uncertain treatment regimens (n = 2), and severe clinical co-morbidities (n = 3). The treatment regimens used were azithromycin (AZM) and ethambutol (EB) for M. gordonae and M. colombiense; AZM + meropenem for M. shimoidei; clarithromycin (CAM) + levofloxacin for M. fortuitum; and CAM + EB + rifampicin for M. gordonae. Among the five treated patients, sputum smear conversion after treatment was achieved in three (60.0%) patients, with a median treatment duration of 11 months (range, 1–24 months). Of these three patients who achieved sputum smear conversion, two achieved sputum conversion within 2 months and one within 1 month. In the five treated patients, improvement was observed in two (40.0%), no change in one (20.0%), and deterioration in two (40.0%): diarrhoea was observed in three patients and was the most frequently reported adverse event, all Grade 2, followed by nausea, observed in two patients, all Grade 2. Next, a skin rash was observed in a patient, graded as Grade 1. Among the 12 untreated patients, 5 (41.7%) remained unchanged, whereas 7 (58.3%) deteriorated. Table 1. Identified rare non-tuberculous mycobacterial (NTM) species. NTM species All patients (n = 45) Patients meeting the diagnostic criteriaA (n = 17) Clinical outcome for patients meeting the diagnostic criteriaA (n = 17) Improvement No change Deterioration M. gordonae 8 (17.8) 3 (17.6) 2 (11.8) 1 (5.9) M. lentiflavum 8 (17.8) 4 (23.5) 1 (5.9) 3 (17.6) M. fortuitum 7 (15.6) 2 (11.8) 1 (5.9) 1 (5.9) M. mageritense 4 (8.9) M. paragordonae 4 (8.9) 3 (17.6) 1 (5.9) 2 (11.8) M. mucogenicum 2 (4.4) M. paraense 2 (4.4) M. chelonae 1 (2.2) M. colombiense 1 (2.2) 1 (5.9) 1 (5.9) M. mantenii 1 (2.2) 1 (5.9) 1 (5.9) M. paraffinicum 1 (2.2) M. septicum 1 (2.2) M. shimoidei 1 (2.2) 1 (5.9) 1 (5.9) M. shinjukuense 1 (2.2) 1 (5.9) 1 (5.9) M. szulgai 1 (2.2) M. wolinskyi 1 (2.2) M. xenopi 1 (2.2) 1 (5.9) 1 (5.9) A ATS/ERS/ESCMID/IDSA diagnostic criteria for non-tuberculous mycobacteria. Open in new tab Table 2. Clinical course of the treated and untreated patients. Clinical course Treated patients (n = 5) Untreated patients (n = 12) Outcome Improvement 2 (40.0) 0 (0.0) No change 1 (20.0) 5 (41.7) Deterioration 2 (40.0) 7 (58.3) Treatment regimen AZM + EB 2 (40.0) — CAM + EB + RFP 1 (20.0) — CAM + LVFX 1 (20.0) — AZM + MEPM 1 (20.0) — Duration of treatment 11 (1–24) — Sputum smear conversion after treatment 3 (60.0) — Reason for no treatment Patient refusal — 7 (58.3) Uncertainty regarding the optimal treatment regimen — 2 (16.7) Presence of severe co-morbidities — 3 (25.0) [i] AZM = azithromycin; EB = ethambutol; RFP = rifampicin; CAM = clarithromycin; LVFX = levofloxacin; MEPM = meropenem. Open in new tab This study demonstrates that a highly diverse range of rare NTM species can be detected, even within a single centre. However, most detections did not fulfil the diagnostic criteria,2 supporting the interpretation that a substantial proportion of rare NTM isolates represent colonisation rather than clinically significant disease. Among the patients meeting the diagnostic criteria,2 only 29.4% received treatment. This low treatment proportion likely reflects the combination of i) limited evidence and lack of guideline-endorsed regimens for most rare species and ii) patient-related constraints in real-world practice. In our cohort, the median age was 76.5 years, and co-morbidities such as COPD (23.5%) and malignancy were common. These host factors increase vulnerability to adverse events, drug-drug interactions, and treatment discontinuation during prolonged multidrug therapy, and therefore may raise the threshold for treatment initiation even when diagnostic criteria are met. The predominance of patient refusal further underlines the importance of shared decision making for rare NTM lung disease, where the uncertainty in expected benefits is often substantial. Radiologically, the NB type accounted for 76.5% of cases meeting the criteria, whereas the FC type was uncommon (11.8%). Although NB is frequently viewed as less aggressive than FC, our CT-based follow-up showed deterioration in 58.3% of untreated patients, indicating that the NB-predominant type due to rare species is not necessarily indolent. Conversely, the outcomes in treated patients were heterogeneous: CT improvement occurred in 40.0% and deterioration in 40.0% of patients, with sputum smear conversion achieved in 60.0% of patients. These mixed results likely reflect inter-species differences in antimicrobial susceptibility and virulence as well as the pragmatic and non-standardised nature of regimen selection. Importantly, the outcome assessment in this study relied on CT changes, whereas the standardised composite outcome definitions for NTM lung disease incorporated microbiological and clinical domains.9 Small-scale clinical reports concerning specific rare NTM species are occasionally encountered; however, the evidence for this has not yet been established.10–12 In the absence of established regimens for rare species, macrolide-based combinations analogous to MAC therapy were used in this cohort. This practice is understandable given that the current major guidelines focus primarily on MAC, M. abscessus, and M. kansasii, leaving clinicians to individualise management for other species.2,5 Nevertheless, extrapolation from MAC should be undertaken cautiously because rare species include both slowly and rapidly growing mycobacteria with markedly different drug susceptibility patterns and resistance mechanisms. Therefore, species-level identification, careful longitudinal assessment of the disease trajectory, and susceptibility-guided regimen construction, where available, are essential for optimising outcomes in rare NTM lung disease. This study has several limitations. First, it was retrospective, had a small sample size, and was conducted at a single centre, which may reduce the generalisability and introduce selection bias in diagnostic testing and treatment decisions. Second, the treatment regimens were heterogeneous and selected pragmatically without a standardised protocol, making it difficult to attribute outcomes to specific drugs or combinations. Third, clinical outcomes were assessed primarily using CT findings. Microbiological endpoints, such as sustained culture conversion based on serial sputum cultures and symptom trajectories, were not uniformly available and may have led to outcome misclassification. Finally, the follow-up duration and timing of imaging assessments were not standardised. In conclusion, a wide diversity of rare NTM species was detected at a single centre. However, most isolates did not fulfil the diagnostic criteria and were presumed to represent colonisation rather than active disease. Among the patients meeting the diagnostic criteria, fewer than one third received treatment, reflecting substantial uncertainty regarding optimal regimens and important patient-related constraints. Acknowledgements Funding: Part of this research was funded by a Grant-in-Aid for Scientific Research (Category C: 25K11445). Data are available from the corresponding author upon reasonable request. Conflict of interest: YY is the Chief Executive Officer of HiLung. The other authors declare no conflicts of interest. References ↵ Hamed KA, Tillotson G. A narrative review of nontuberculous mycobacterial pulmonary disease: microbiology, epidemiology, diagnosis, and management challenges. Expert Rev Respir Med. 2023;17(11):973-988. Google Scholar OpenURL PubMed ↵ Daley CL, Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):e1-e36. Google Scholar OpenURL CrossRef PubMed ↵ Hoefsloot W, The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Resp J. 2013;42(6):1604-1613. Google Scholar OpenURL CrossRef Abstract / Full Text PubMed Web of Science ↵ Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med. 2015;36(1):13-34. Google Scholar OpenURL CrossRef PubMed ↵ Griffith DE, An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367-416. Google Scholar OpenURL CrossRef PubMed Web of Science ↵ van Ingen J, Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Resp J. 2018;51(3):1800170. Google Scholar OpenURL CrossRef Abstract / Full Text PubMed ↵ Namkoong H, Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis. 2016;22(6):1116-1117. Google Scholar OpenURL CrossRef PubMed ↵ Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis. 2014;18(11):1370-1377. Google Scholar OpenURL CrossRef PubMed ↵ US National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Bethesda, MD, USA: National Cancer Institute, 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.html. Google Scholar ↵ Kim SR, Clinical characteristics and treatment outcomes of Mycobacterium fortuitum pulmonary disease. Microbiol Spectr. 2023;11(4):e0205123. Google Scholar OpenURL ↵ Li Y, Mycobacterium paragordonae is an emerging pathogen in human pulmonary disease: clinical features, antimicrobial susceptibility testing and outcomes. Emerg Microbes Infect. 2022;11(1):1973-1981. Google Scholar OpenURL PubMed ↵ Baird TM, Mycobacterium shimoidei, a rare pulmonary pathogen, Queensland, Australia. Emerg Infect Dis. 2017;23(11):1919-1922. Google Scholar OpenURL PubMed Tables Table 1. Identified rare non-tuberculous mycobacterial (NTM) species. NTM species All patients (n = 45) Patients meeting the diagnostic criteriaA (n = 17) Clinical outcome for patients meeting the diagnostic criteriaA (n = 17) Improvement No change Deterioration M. gordonae 8 (17.8) 3 (17.6) 2 (11.8) 1 (5.9) M. lentiflavum 8 (17.8) 4 (23.5) 1 (5.9) 3 (17.6) M. fortuitum 7 (15.6) 2 (11.8) 1 (5.9) 1 (5.9) M. mageritense 4 (8.9) M. paragordonae 4 (8.9) 3 (17.6) 1 (5.9) 2 (11.8) M. mucogenicum 2 (4.4) M. paraense 2 (4.4) M. chelonae 1 (2.2) M. colombiense 1 (2.2) 1 (5.9) 1 (5.9) M. mantenii 1 (2.2) 1 (5.9) 1 (5.9) M. paraffinicum 1 (2.2) M. septicum 1 (2.2) M. shimoidei 1 (2.2) 1 (5.9) 1 (5.9) M. shinjukuense 1 (2.2) 1 (5.9) 1 (5.9) M. szulgai 1 (2.2) M. wolinskyi 1 (2.2) M. xenopi 1 (2.2) 1 (5.9) 1 (5.9) A ATS/ERS/ESCMID/IDSA diagnostic criteria for non-tuberculous mycobacteria. Open in new tab Table 2. Clinical course of the treated and untreated patients. Clinical course Treated patients (n = 5) Untreated patients (n = 12) Outcome Improvement 2 (40.0) 0 (0.0) No change 1 (20.0) 5 (41.7) Deterioration 2 (40.0) 7 (58.3) Treatment regimen AZM + EB 2 (40.0) — CAM + EB + RFP 1 (20.0) — CAM + LVFX 1 (20.0) — AZM + MEPM 1 (20.0) — Duration of treatment 11 (1–24) — Sputum smear conversion after treatment 3 (60.0) — Reason for no treatment Patient refusal — 7 (58.3) Uncertainty regarding the optimal treatment regimen — 2 (16.7) Presence of severe co-morbidities — 3 (25.0) [i] AZM = azithromycin; EB = ethambutol; RFP = rifampicin; CAM = clarithromycin; LVFX = levofloxacin; MEPM = meropenem. Open in new tab Article usage Cited by Crossref Close Crossref Citing Articles No crossref citations found for this article Google Scholar Article Information vol. 3 no. 6 Page: 417-419 DOI https://doi.org/10.5588/ijtldopen.26.0123 History Received 3 March 2026 Accepted 16 March 2026 Published online 1 June 2026 Copyright & Usage © 2026 The Authors This is an open access article published by The Union under the terms of the Creative Commons Attribution License CC-BY. Author Information Fujita, K. Kanai, O. Fujimoto, N. Yoshimura, S. Toyama, S. Ito, T. Imakita, T. Oi, I. Yamamoto, Y. Tanizawa, K. Focus Previous Next

  • Open Access

    Bronchoscopic removal of lower airway foreign body: a two-center retrospective cohort study

    by Shogo Toyama, Kenichiro Kudo, Kohei Fujita, Yuki Takigawa, Hiromi Watanabe, Issei Oi, Osamu Kanai, Ken Sato, Keiichi Fujiwara, Kiminobu Tanizawa, et al.

    Background: Tracheobronchial foreign body (FB) aspiration is a life-threatening condition, particularly in older adults. Despite its clinical significance, research on the etiology of adult FB aspiration, as well as real-world outcomes and complications associated with FB removal in lower airways, remains limited. Patients and methods: This was a two-center retrospective cohort study in Japan. We included adult patients aged 18 years or older who underwent bronchoscopic FB removal between April 2010 and March 2025. Results: A total of 28 patients were included in this analysis (mean age, 75.4 years [median age: 75 years]; range, 55–102 years). Nineteen patients (67.9%) were male. The most frequently reported symptoms were coughing (46.4%), sputum production (39.3%), and dyspnea (17.9%). A total of 30 FBs were identified, with dental prostheses (60.0%) being the most common type, followed by natural teeth (10.0%). FBs were slightly more common on the right side (53.3%) than on the left side (43.3%), with the right lower lobe being the most frequent site of lodgement (30.0%), followed by the left lower lobe (20.7%). The most frequently bronchoscopic findings were mucosal edema (36.7%) and bleeding (26.7%). FB removal was performed using flexible bronchoscopy in 26 patients (92.9), with the exception of two cases (7.1%) in which rigid bronchoscopy was employed. Bronchoscopy was performed in the endoscopy room for 21 patients (75.0%). Among the 28 patients, standard forceps were used in 24 (85.7%), followed by basket forceps, which was employed in 10 patients (35.7%). FB removal was successful in 26 (92.9%) patients. Regarding adverse events, hypoxia was the only complication observed, occurring in 18 patients (64.3%); no other adverse events were reported. Conclusions: Most FB in the lower airways can be successfully and safely removed via flexible bronchoscopy.

  • Open Access

    Safety and Efficacy of CT-Guided Lung Biopsy in Elderly Patients age 75 Years and Older: A Single-Centre Retrospective Comparative Study

    by Saiki Yoshimura, Osamu Kanai, Kohei Fujita, Naoki Fujimoto, Yuta Okada, Shogo Toyama, Takanori Ito, Takuma Imakita, Issei Oi, Kiminobu Tanizawa

    Introduction: CT-guided biopsy has good diagnostic accuracy, but adverse events such as pneumothorax are common. There are few reports on the safety and efficacy of CT-guided biopsy in the elderly. Methods: This was a retrospective single-centre cohort study. Patients who underwent CT-guided lung biopsy between February 2017 and August 2024 were included. Patient background, disease background, examination status, and adverse events were ascertained. Elderly were defined as those aged 75 years and older. The primary outcome was the incidence of all adverse events, and the secondary outcomes were the incidence of pneumothorax and diagnostic accuracy. Categorical variables were compared by Chi-square test, and continuous variables by t-test. Multivariable analysis was performed by logistic regression analysis adjusted for age, sex, lung comorbidities, and radiological findings of target lesion. Results: There were significant differences between the two groups in ECOG-PS and the distance from the surface to pleura and target. In the primary outcome, any adverse events occurred in 207 patients (56.2%), with no significant difference between elderly (97/180, 53.9%) and non-elderly (110/188, 58.5%) patients ( p = 0.401). Pneumothorax was the most common adverse event, occurring in 151 (41.0%) patients, with no significant difference between elderly (68/180, 37.8%) and non-elderly (83/188, 44.1%) ( p = 0.244). On multivariate analysis, elderly (75years or older) was not clearly associated with the occurrence of all or severe adverse events, pneumothorax, and confirmed diagnosis. Location in the lower lung field and distant from the pleura were significantly associated with the incidence of all adverse event. In the secondary outcomes, emphysema or interstitial pneumonia, location in the lower lung field, and distant from the pleura were significantly associated with pneumothorax. There was no significant difference in the diagnostic accuracy disease between the elderly and non-elderly patients. Conclusions: The incidence of adverse events and diagnostic accuracy of CT-guided biopsy are similar in elderly and non-elderly patients, and this method is useful even in elderly patients. Key point The safety and efficacy of CT-guided lung biopsy in elderly patients are equivalent to those in non-elderly patients.

  • Open Access

    Reconsidering the Role of Blood Cultures in Community‐Acquired Pneumonia: A Case of Co‐Infection With Streptococcus pneumoniae and Klebsiella variicola

    by Naoki Fujimoto, Issei Oi, Kohei Fujita, Saiki Yoshimura, Takanori Ito, Takuma Imakita, Osamu Kanai, Kiminobu Tanizawa

    Community‐acquired pneumonia ( CAP ) remains a leading cause of morbidity and mortality. Streptococcus pneumoniae is the most common causative pathogen, with urinary antigen testing aiding the diagnosis thereof; however, blood culture yields are low, and guideline recommendations vary. We herein report a case of a 77‐year‐old man with pneumococcal pneumonia confirmed by urinary antigen testing whose blood cultures also revealed Klebsiella variicola . The detection of this co‐infection would have been missed without blood cultures. Moreover, this combination of pathogens is first reported. This case underscores the importance of routine blood cultures in CAP diagnosis and supports the Japanese Respiratory Society's recommendation for their use in hospitalised patients.

  • Open Access

    A Case of Miliary Tuberculosis Complicated by Knee Joint Tuberculosis

    by Saiki Yoshimura, Kentaro Satomi, Kohei Fujita, Hiromasa Tachibana, Yuta Okada, Naoki Fujimoto, Shogo Toyama, Takanori Ito, Takuma Imakita, Issei Oi, et al.

    This case report details a 75‐year‐old male diagnosed with miliary tuberculosis (TB) who subsequently developed tuberculous arthritis in his left knee. The patient was initially admitted for a hemorrhagic gastric ulcer, where chest imaging and positive cultures from multiple sites confirmed miliary TB. Standard antitubercular therapy was started, but 6 weeks later, he presented with worsening pain and swelling in his left knee. A joint aspiration and MRI confirmed tuberculous arthritis with an abscess, which necessitated surgical debridement in addition to the drug regimen. We emphasize that orthopaedic TB often requires surgical intervention alongside medication for successful treatment. While total knee arthroplasty can be an effective treatment for joint destruction, the previous report suggests that it should be delayed until after a prolonged course of antitubercular therapy (e.g., 12 months or more) to prevent recurrence.

  • Open Access

    Single-centre retrospective experience of complications and outcomes of computed tomography-guided lung biopsy and interventions for the management of intrathoracic infections

    by Kohei Fujita, Naoki Fujimoto, Saiki Yoshimura, Shogo Toyama, Takanori Ito, Takuma Imakita, Issei Oi, Osamu Kanai, Yuki Yamamoto, Kiminobu Tanizawa

    Objective: To investigate the complications and outcomes of computed tomography (CT)-guided lung biopsy and interventions in the management of intrathoracic infections. Results: Twenty-nine patients were examined. Eleven (37.9%) patients were diagnosed with pulmonary nodules, and 18 (62.1%) underwent drainage of lung abscesses. The median age of the patients was 77 years, and 44.8% had a poor performance status. The major underlying diseases were hypertension and malignancies. The puncture site was mostly the right lower lobe (44.8%), whereas there were no cases of puncture in the left upper lobe. The nodule diagnostic success rate was 54.5% and the success rate of lung abscess drainage was 88.9%. The common organisms identified were Aspergillus , S. pneumoniae and S. aureus in the nodules and S. intermedius in the lung abscess drainage. Pigtail catheters were most commonly used for drainage (50%). Pneumothorax and hypoxaemia were the most common adverse events (13.8%), followed by fever (10.3%). Clinical trial registration : This retrospective study was registered in the UMIN Clinical Trials Registry (registration No. UMIN000055755). This clinical trial was registered on 6 October 2024 and is publicly available.